Find-A-Study

A Phase III, Randomized, Open-Label, Multicenter Study of Lurbinectedin in Combination with Atezolizumab Compared with Atezolizumab as Maintenance Therapy in Participants with Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following First-Line Induction Therapy with Carboplatin, Etoposide and Atezolizumab (CTMS# 22-0017)

Lay Description

Category

Cancers and Other Neoplasms
Lungs, Breathing and Bronchial

IRB Number: 20220147HU
NCT Number: NCT # not yet entered

Eligibility

Eligible Ages
Eligible Genders
Accepts Healthy Volunteers

Inclusion Criteria

Exclusion Criteria

Study Design

Arm Groups

Study Contact